Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Eli Lilly Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (71)
Cancellation by sponsor (69)
Australian Public Assessment Report (AusPAR) (21)
Prescription medicine registration (21)
Designation or determination (4)
Prescription medicine decision summary (4)
Prescription medicine evaluation (4)

Date

2026 (9)
2025 (28)
2024 (21)
2023 (21)
2022 (15)
2021 (10)
2020 (4)
2019 (34)
2018 (14)
2017 (1)
2016 (2)
2015 (5)
2014 (2)
2013 (4)
2012 (1)
2011 (2)
2010 (1)
2008 (2)
2007 (1)
2006 (1)
2004 (1)
2002 (2)
1999 (4)
1998 (1)
1996 (2)
1992 (4)
1991 (2)

Search

Sponsor content

194 result(s) found, displaying 101 to 110

HUMULIN NPH KWIKPEN biosynthetic human isophane insulin 100IU/mL injection multidose syringe Cancelled under Section 30(1)(c) of the Act

22 June 2021

Cancellation by sponsor

Requested by Eli Lilly Australia Pty Ltd
HUMULIN 30/70 KWIKPEN biosynthetic human 30% neutral 70% isophane insulin 100IU/mL injection multidose syringe Cancelled under Section 30(1)(c) of the Act

22 June 2021

Cancellation by sponsor

Requested by Eli Lilly Australia Pty Ltd
TALTZ (Eli Lilly Australia Pty Ltd)

28 May 2021

Prescription medicine registration

Active ingredients: ixekizumab.
AusPAR: Baricitinib

20 May 2021

Australian Public Assessment Report (AusPAR)

Australian Public Assessment Report for Baricitinib
EFFIENT prasugrel (as hydrochloride) 5 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

20 May 2021

Cancellation by sponsor

Requested by Eli Lilly Australia Pty Ltd
EFFIENT prasugrel (as hydrochloride) 10 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

20 May 2021

Cancellation by sponsor

Requested by Eli Lilly Australia Pty Ltd
ANDEPRA duloxetine 60 mg (as hydrochloride) enteric capsule blister pack Cancelled under Section 30(1)(c) of the Act

14 May 2021

Cancellation by sponsor

Requested by Eli Lilly Australia Pty Ltd
ANDEPRA duloxetine 30 mg (as hydrochloride) enteric capsule blister pack Cancelled under Section 30(1)(c) of the Act

14 May 2021

Cancellation by sponsor

Requested by Eli Lilly Australia Pty Ltd
OLUMIANT (Eli Lilly Australia Pty Ltd)

3 February 2021

Prescription medicine registration

Active ingredients: baricitinib.
OLUMIANT baricitinib 2 mg film-coated tablet blister pack (277905)

23 January 2018

ARTG

Australian Register of Therapeutic Goods (ARTG) information for OLUMIANT baricitinib 2 mg film-coated tablet blister pack.

Pages

First page
Previous page
…
Page 7
Page 8
Page 9
Page 10
Current page 11
Page 12
Page 13
Page 14
Page 15
…
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.